MAPT and Alzheimer disease: Blood-based biomarkers, including Aβ42 and various forms of phospho-tau, might replace CSF and PET biomarkers in the future, since they are easily obtained, not only for initial diagnosis but also for repeated follow-up [82]; however, sensitivity and specificity to effectively discriminate AD from other dementias still has to be established [83].